NCT00543972View on ClinicalTrials.gov

Dose Escalation Safety and Pharmacokinetic Study of AVE9633 as Single Agent in Relapsed/Refractory CD33-Positive Acute Myeloid Leukemia

PHASE1TerminatedINTERVENTIONAL

Enrollment

12

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

August 31, 2008

Study Completion Date

August 31, 2008

Conditions

Myeloid Leukemia

Interventions

DRUG

AVE9633

Intravenous Infusion

Trial Locations (3)

08807

Sanofi-Aventis Administrative Office, Bridgewater

Unknown

Sanofi-Aventis Administrative Office, Paris

Sanofi-Aventis Administrative Office, Barcelona

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Sanofi

INDUSTRY